Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet

References

• UKPDS 34Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) GroupLancet1998352854659742977
   PubMed Web of Science ®Google Scholar
• AhrenBGlucagon secretion in relation to insulin sensitivity in healthy subjectsDiabetologia2006491172216362283
   PubMed Web of Science ®Google Scholar
• AhrenBGomisRStandlETwelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetesDiabetes Care2004a2728748015562200
   PubMed Web of Science ®Google Scholar
• AhrenBLandin-OlssonMJanssonPAInhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetesJ Clin Endocrinol Metab2004b8920788415126524
   PubMed Web of Science ®Google Scholar
• AhrenBPaciniGFoleyJEImproved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 yearDiabetes Care20052819364016043735
   PubMed Web of Science ®Google Scholar
• AhrenBPaciniGTuraAImproved meal-related insulin processing contributes to the enhancement of B-Cell Function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetesHorm Metab Res200739826917992639
   PubMed Web of Science ®Google Scholar
• AhrénBPratleyRESoubtMClinical measures of islet function: usefulness to characterize defects in diabetesCurr Diabetes Rev2008in Press
   PubMedGoogle Scholar
• AyalasomayajulaSPDoleKHeYLEvaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjectsCurr Med Res Opin20072329132017931461
   PubMed Web of Science ®Google Scholar
• AzumaKRadikovaZMancinoJMeasurements of islet function and glucose metabolism with the DPP-4 inhibitor vildagliptin in patients with type 2 diabetesJ Clin Endocrinol Metab2007
   PubMed Web of Science ®Google Scholar
• BaileyCJTurnerRCMetforminN Engl J Med199633457498569826
   PubMed Web of Science ®Google Scholar
• BalasBBaigMRWatsonCThe dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patientsJ Clin Endocrinol Metab20079212495517244786
   PubMed Web of Science ®Google Scholar
• BalkrishnanRRajagopalanRCamachoFTPredictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort studyClin Ther20032529587114693318
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSFixed-dose combinations improve medication compliance: a meta-analysisAm J Med20071207131917679131
   PubMed Web of Science ®Google Scholar
• BolliGDottaFRochotteEEfficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind studyDiabetes Obes Metab200810829018034842
   PubMed Web of Science ®Google Scholar
• BosiECamisascaRPColloberCEffects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminDiabetes Care2007a30890517277036
   PubMed Web of Science ®Google Scholar
• BosiEShaoQCohenSEImproved blood pressure (BP) lowering in hypertensive patients (pts) with type 2 diabetes (T2DM) with vildagliptin combined with metformin compared with metformin aloneDiabetes2007b56A549
   Web of Science ®Google Scholar
• BrownJBNicholsGAPerryAThe burden of treatment failure in type 2 diabetesDiabetes Care20042715354015220224
   PubMed Web of Science ®Google Scholar
• BrownJBPedulaKBarzilayJLactic acidosis rates in type 2 diabetesDiabetes Care1998211659639773726
   PubMed Web of Science ®Google Scholar
• BurkeyBFRussellMWangKVildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not DPP-8 or DPP-9Diabetologia2006494778
   Web of Science ®Google Scholar
• ButlerAEJansonJBonner-WeirSBeta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetesDiabetes2003521021012502499
   PubMed Web of Science ®Google Scholar
• ConsoliAGomisRHalimiSInitiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complicationsDiabetes Metab2004305091615671920
   PubMed Web of Science ®Google Scholar
• CookMNGirmanCJSteinPPInitial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary careDiabet Med200724350817335466
   PubMed Web of Science ®Google Scholar
• CramerJAA systematic review of adherence with medications for diabetesDiabetes Care20042712182415111553
   PubMed Web of Science ®Google Scholar
• DeFronzoRAGoodmanAMEfficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study GroupN Engl J Med199533354197623902
   PubMed Web of Science ®Google Scholar
• DejagerSRazacSFoleyJEVildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose studyHorm Metab Res2007392182317373638
   PubMed Web of Science ®Google Scholar
• DeziiCMKawabataHTranMEffects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetesSouth Med J200295687111827247
   PubMed Web of Science ®Google Scholar
• DonnellyLADoneyASHattersleyATThe effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetesDiabet Med2006231283316433709
   PubMed Web of Science ®Google Scholar
• DunningBELigueros-SaylanMD’AlessioDADifferential effects of DPP-4 inhibition on incretin hormone levels in drug-naive and metformin-treated patients with type 2 diabetesDiabetologia20064911011
   Web of Science ®Google Scholar
• DuttaroyAVoelkerFZhangXThe DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in rodentsDiabetologia200548A178
   Web of Science ®Google Scholar
• El OuaghlidiARehringEHolstJJThe dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretionJ Clin Endocrinol Metab20079241657117698900
   PubMed Web of Science ®Google Scholar
• FonsecaVSchweizerAAlbrechtDAddition of vildagliptin to insulin improves glycaemic control in type 2 diabetesDiabetologia20075011485517387446
   PubMed Web of Science ®Google Scholar
• GarberAJCamisascaRPJauffretSEfficacy and tolerability of vildagliptin added to a sulfonylurea (SU) in patients with type 2 diabetes (T2DM)Diabetes2007a56A134
   Web of Science ®Google Scholar
• GarberAJSchweizerABaronMAVildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyDiabetes Obes Metab2007b91667417300592
   PubMed Web of Science ®Google Scholar
• GolayAMetformin and body weightInt J Obes (Lond)2007
   PubMedGoogle Scholar
• GoodarziMOBryer-AshMMetformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agentsDiabetes Obes Metab200576546516219009
   PubMed Web of Science ®Google Scholar
• GrantRWDevitaNGSingerDEPolypharmacy and medication adherence in patients with type 2 diabetesDiabetes Care20032614081212716797
   PubMed Web of Science ®Google Scholar
• GreenBDIrwinNDuffyNAInhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1Eur J Pharmacol2006547192916945366
   PubMed Web of Science ®Google Scholar
• GuillausseauPJInfluence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practiceDiabetes Metab200329798112629452
   PubMed Web of Science ®Google Scholar
• HalimiSMetformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes managementDiabetes Metab200632555617296508
   PubMed Web of Science ®Google Scholar
• HeYLSaboRRiviereGJEffect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsCurr Med Res Opin2007a231131817519080
   PubMed Web of Science ®Google Scholar
• HeYLSaboRSunkaraGEvaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteersJ Clin Pharmacol2007b47998100417660482
   PubMed Web of Science ®Google Scholar
• HeYLSadlerBMSaboRThe absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteersClin Pharmacokinet2007c4678780217713976
   PubMed Web of Science ®Google Scholar
• HeYLSerraDWangYPharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitusClin Pharmacokinet2007d465778817596103
   PubMed Web of Science ®Google Scholar
• HeYLWangYBullockJMPharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTTJ Clin Pharmacol2007e476334117442688
   PubMed Web of Science ®Google Scholar
• HinkeSAKuhn-WacheKHoffmannTMetformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1Biochem Biophys Res Commun2002a2911302811883961
   PubMed Web of Science ®Google Scholar
• HinkeSAMcIntoshCHHoffmannTOn combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitorsDiabetes Care2002b251490112145269
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med200635524274317145742
   PubMed Web of Science ®Google Scholar
• KahnSEPrigeonRLMcCullochDKQuantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic functionDiabetes1993421663728405710
   PubMed Web of Science ®Google Scholar
• KardasPThe DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes)Diabetes Obes Metab20057722816219016
   PubMed Web of Science ®Google Scholar
• KoroCEBowlinSJBourgeoisNGlycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary reportDiabetes Care200427172014693960
   PubMed Web of Science ®Google Scholar
• LangleyAKSuffolettaTJJenningsHRDipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitusPharmacotherapy20072711638017655515
   PubMed Web of Science ®Google Scholar
• LauDTNauDPOral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetesDiabetes Care20042721495315333476
   PubMed Web of Science ®Google Scholar
• LindsayJRDuffyNAMcKillopAMInhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetesDiabet Med200522654715842525
   PubMed Web of Science ®Google Scholar
• MannucciEOgnibeneACremascoFEffect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjectsDiabetes Care2001244899411289473
   PubMed Web of Science ®Google Scholar
• MariASallasWMHeYLVildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetesJ Clin Endocrinol Metab20059048889415886245
   PubMed Web of Science ®Google Scholar
• MariAScherbaumWANilssonPMCharacterization of the influence of vildagliptin on model-assessed {beta}-cell function in patients with type 2 diabetes and mild hyperglycemiaJ Clin Endocrinol Metab2007
   Web of Science ®Google Scholar
• MatikainenNManttariSSchweizerAVildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetesDiabetologia20064920495716816950
   PubMed Web of Science ®Google Scholar
• MelikianCWhiteTJVanderplasAAdherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapyClin Ther200224460711952029
   PubMed Web of Science ®Google Scholar
• MigoyaEMMillerJLarsonPSitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrationsDiabetes200756A74
   Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinedionesDiabetologia20085181118026926
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20062919637216873813
   PubMed Web of Science ®Google Scholar
• NathanDMDavidsonMBDeFronzoRAImpaired fasting glucose and impaired glucose tolerance: implications for careDiabetes Care200730753917327355
   PubMed Web of Science ®Google Scholar
• NicholsGAAlexanderCMGirmanCJTreatment escalation and rise in HbA1c following successful initial metformin therapyDiabetes Care200629504916505496
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med20053534879716079372
   PubMed Web of Science ®Google Scholar
• PaesAHBakkerASoe-AgnieCJImpact of dosage frequency on patient complianceDiabetes Care1997201512179314626
   PubMed Web of Science ®Google Scholar
• Pi-SunyerFXSchweizerAMillsDEfficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetesDiabetes Res Clin Pract200776132817223217
   PubMed Web of Science ®Google Scholar
• PladevallMWilliamsLKPottsLAClinical outcomes and adherence to medications measured by claims data in patients with diabetesDiabetes Care2004272800515562188
   PubMed Web of Science ®Google Scholar
• PratleyRERosenstockJPi-SunyerFXManagement of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapyDiabetes Care2007a3030172217878242
   PubMed Web of Science ®Google Scholar
• PratleyRESchweizerARosenstockJRobust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy databaseDiabetes Obes Metab2007b
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMACamisascaRPEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes Obes Metab2007a91758517300593
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMADejagerSComparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabetes Care2007b302172317259484
   PubMed Web of Science ®Google Scholar
• RosenstockJFoleyJERendellMEffects of the DPP-4 inhibitor vildagliptin on incretin hormones islet function and postprandial glycemia in subjects with impaired glucose toleranceDiabetes Care2007c
   Web of Science ®Google Scholar
• SchectmanJMNadkarniMMVossJDThe association between diabetes metabolic control and drug adherence in an indigent populationDiabetes Care20022510152112032108
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariAEfficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes (T2DM) and mild hyperglycemiaDiabetes200756A134
   Web of Science ®Google Scholar
• SchweizerACouturierAFoleyJEComparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetesDiabet Med2007249556117509069
   PubMed Web of Science ®Google Scholar
• StumvollMNurjhanNPerrielloGMetabolic effects of metformin in non-insulin-dependent diabetes mellitusN Engl J Med199533355047623903
   PubMed Web of Science ®Google Scholar
• SunkaraGSaboRWangYDose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteersJ Clin Pharmacol2007471152817656620
   PubMed Web of Science ®Google Scholar
• TahraniAAVarugheseGIScarpelloJHMetformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?BMJ20073355081217823192
   PubMed Web of Science ®Google Scholar
• TourrelCBailbeDLacorneMPersistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4Diabetes20025114435211978641
   PubMed Web of Science ®Google Scholar
• TurnerRCCullCAFrighiVGlycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) GroupJAMA199928120051210359389
   PubMed Web of Science ®Google Scholar
• UtzschneiderKMTongJMontgomeryBThe dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucoseDiabetes Care2008311081317909087
   PubMed Web of Science ®Google Scholar
• VirallyMBlickleJFGirardJType 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectivesDiabetes Metab2007332314417703979
   PubMed Web of Science ®Google Scholar
• VellaABockGGieslerPDEffects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetesDiabetes20075614758017303799
   PubMed Web of Science ®Google Scholar
• ZanderMTaskiranMToft-NielsenMBAdditive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetesDiabetes Care200124720511315837
   PubMed Web of Science ®Google Scholar